Positive Phase III sets stage for levomilnacipran NDA

Investigators at Forest Laboratories ($FRX) and Pierre Fabre Medicament say they're on track to file an NDA for the anti-depression drug levomilnacipran after racking up a fresh set of positive Phase III data. The study was the second of three late-stage clinical trials of the drug. "We have successfully completed two positive Phase III studies for the treatment of MDD in adults and plan to file a new drug application for levomilnacipran with the FDA later this year," said Dr. Marco Taglietti, the head of R&D at the Forest Research Institute. The application is slated for later this year with another Phase III readout expected soon. Release
 

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.